Abstract

  Brain tumours represent a group of neoplasms arising from brain tissue each with their own unique biology prognosis and treatment. Included in these groups are neoplasms not arising from brain parenchyma’s which encompass meningioma’s lymphomas and metastatic disease from other primary sources. Despite the diverse group of neoplasms represented, most intracranial tumours follow similar clinical presentations and diagnostic workups methods. The majority of primary brain tumours fall under the WHO classification scheme of tumours of neuro epithelial tissue. There are over 120 brain tumour classifications defined by the WHO, based on the tumour cell type and location, making this a very complex diagnosis. The present review mainly described that diagnosis and therapeutic advancements of few types of brain tumors.

Keywords: Brain Tumor; Neoplasm; Brain Parenchyma; Lympoma; Metastatic

References

1. Roux FE., et al. “Methodological and technical issues for integrating functional magnetic resonance imaging data in a neuronavigational system”. Neurosurgery 49 (2001): 1145-1156.
2. Kim SS., et al. “Awake Craniotomy for Brain Tumors Near Eloquent Cortex: Correlation of Intraoperative Cortical Mapping With Neurological Outcomes in 309 Consecutive Patients”. Neurosurgery 64 (2009) 836-846.
3. Ohgaki H., et al. “Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas”. Journal of Neuropathology and Experimental Neurology 64 (2005): 479-489.
4. Chaichana KL., et al. “Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas”. Journal of Neurosurgery 112 (2010): 10-17.
5. Adamson C., et al. “Glioblastoma multiforme: a review of where we have been and where we are going”. Expert Opinion on Investigational Drugs 18 (2009): 1061-1083.
6. Ostrom Q., et al. “Gene markers in brain tumors: what the epileptologist should know”. Epilepsia9 (2013): 25-29.
7. Esteller M., et al. “Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents”. The New England Journal of Medicine 343 (2000): 1350-1354.
8. Hegi ME., et al. “Clinical Trial Substantiates the Predictive Value of O-6-MethylguanineDNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide”. Clinical Cancer Research 10 (2004): 1871-1874.
9. Hegi ME., et al. “MGMT gene silencing and beneft from temozolomide in glioblastoma”. The New England Journal of Medicine 352 (2005): 997-1003.
10. Mur P., et al. “Codeletion of 1p and 19q determines distinct gene methylation and expression profles in IDH-mutated oligodendroglial tumors”. Acta Neuropathology 126 (2013): 277-289.
11. Cairncross G., et al. “Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Terapy Oncology Group Trial 9402”. Journal of Clinical Oncology 24 (2006): 2707-2714.
12. Van den Bent M., et al. “Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial”. Journal of Clinical Oncology 24 (2006): 2715-2722.
13. Weller M., et al. “Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice”. Neuro Oncology4 (2012): iv100-108.
14. Yan H., et al. “IDH1 and IDH2 mutations in gliomas”. The New England Journal of Medicine 360 (2009): 765-773.
15. Parsons DW., et al. “An integrated genomic analysis of human glioblastoma multiforme”. Science 321 (2008): 1807-1812.
16. Dang L., et al. “Cancer-associated IDH1 mutations produce 2-hydroxyglutarate”. Nature 462 (2009): 739-744.
17. Noushmehr H., et al. “Identifcation of a CpG island methylator phenotype that defnes a distinct subgroup of glioma”. Cancer Cell 17 (2010): 510-522.
18. Turcan S., et al. “IDH1 mutation is sufcient to establish the glioma hypermethylator phenotype”. Nature 483 (2012): 479-483.
19. Del Vecchio CA., et al. “EGFRIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defnes a hierarchy modulated by epigenetic mechanisms”. Oncogene 32 (2013): 2670-2681.
20. Batra S., et al. “Epidermal growth factor ligand-independent, unregulated, cell transforming potential of a naturally occurring human mutant EGFRvIII gene”. Cell Growth Different 6 (1995): 1251-1259.
21. Heimberger AB., et al. “Prognostic Efect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients”. Clinical Cancer Research 11 (2005): 1462-1466.
22. Ekstrand AJ., et al. “Genes for Epidermal Growth Factor Receptor, Transforming Growth Factor a, and Epidermal Growth Factor and Teir Expression in Human Gliomas in Vivo”. Cancer Research 51 (1991): 2164-2172.

Citation

Citation: D Varshith., et al. “An Updated Review on Types of Brain Tumor".Acta Scientific Pharmacology 2.1 (2020): 18-19.

Copyright

Copyright: © 2020 D Varshith., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.